[go: up one dir, main page]

MA33740B1 - Traitement à l'aide de cellules adultes matures reprogrammées - Google Patents

Traitement à l'aide de cellules adultes matures reprogrammées

Info

Publication number
MA33740B1
MA33740B1 MA34857A MA34857A MA33740B1 MA 33740 B1 MA33740 B1 MA 33740B1 MA 34857 A MA34857 A MA 34857A MA 34857 A MA34857 A MA 34857A MA 33740 B1 MA33740 B1 MA 33740B1
Authority
MA
Morocco
Prior art keywords
cells
patient
transdifferentiated
treatment
retrodifferentiated
Prior art date
Application number
MA34857A
Other languages
Arabic (ar)
English (en)
Inventor
Ilham Mohamed Saleh Saeed Abuljadayel
Original Assignee
Tristem Trading Cyprus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tristem Trading Cyprus Ltd filed Critical Tristem Trading Cyprus Ltd
Publication of MA33740B1 publication Critical patent/MA33740B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

L'invention concerne un procédé de traitement de différentes maladies, troubles, ou états chez un patient à l'aide de cellules reprogrammées telles que des cellules rétro-différenciées, transdifférenciées ou redifférenciées. Le procédé comprend l'obtention de cellules provenant du patient, la rétro-différenciation des cellules déterminées de façon à obtenir des cellules cibles rétrodifférenciées, et l'administration des cellules rétrodifférenciées au patient. Dans certains modes de réalisation, le procédé comprend l'obtention de cellules provenant du patient, la transdifférenciation des cellules de façon à obtenir des cellules cibles transdifférenciées, et l'administration des cellules cibles transdifférenciées au patient. Les cellules cibles rétrodifférenciées ou transdifférenciées réparent ou reconstituent un tissu ou des cellules chez le patient.
MA34857A 2009-10-19 2012-05-11 Traitement à l'aide de cellules adultes matures reprogrammées MA33740B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2009/051396 WO2011048350A1 (fr) 2009-10-19 2009-10-19 Traitement à l'aide de cellules adultes matures reprogrammées

Publications (1)

Publication Number Publication Date
MA33740B1 true MA33740B1 (fr) 2012-11-01

Family

ID=42199514

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34857A MA33740B1 (fr) 2009-10-19 2012-05-11 Traitement à l'aide de cellules adultes matures reprogrammées

Country Status (17)

Country Link
EP (1) EP2490702A1 (fr)
JP (1) JP6073135B2 (fr)
KR (1) KR101766203B1 (fr)
CN (1) CN102647989A (fr)
AU (1) AU2009354350B2 (fr)
CA (1) CA2781522A1 (fr)
CH (1) CH704227B1 (fr)
CU (1) CU24006B1 (fr)
IL (1) IL218902A (fr)
MA (1) MA33740B1 (fr)
MX (1) MX2012004522A (fr)
PH (1) PH12012500714A1 (fr)
RU (1) RU2635317C2 (fr)
TN (1) TN2012000157A1 (fr)
UA (1) UA109265C2 (fr)
WO (1) WO2011048350A1 (fr)
ZA (1) ZA201202664B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170296595A1 (en) * 2014-09-18 2017-10-19 North Carolina State University Mammalian Lung Spheroids and Lung Spheroid Cells and Uses Thereof
JP6113133B2 (ja) 2014-11-06 2017-04-12 日本メナード化粧品株式会社 幹細胞の未分化状態維持剤及び増殖促進剤
CN108290939B (zh) 2015-10-16 2023-01-13 纽约市哥伦比亚大学理事会 用于抑制谱系特异性抗原的组合物和方法
CN107114355A (zh) * 2016-08-01 2017-09-01 北京世纪劲得生物技术有限公司 一种脂肪细胞保护液及其制备方法
JP7386082B2 (ja) 2017-02-28 2023-11-24 ブイオーアール バイオファーマ インコーポレーテッド 系統特異的タンパク質の阻害のための組成物および方法
CN109731012A (zh) * 2017-10-30 2019-05-10 邹兆中 提高生物免疫治疗有效物质活性的方法
CN109706119B (zh) * 2018-04-13 2020-11-27 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
EP4512890A3 (fr) 2018-08-28 2025-04-30 Vor Biopharma, Inc. Cellules souches hermatopoietiques génétiquement modifiées et leurs utilisations
KR20200025210A (ko) * 2018-08-29 2020-03-10 주식회사 스템모어 모유두 세포의 배양용 조성물 및 이를 이용한 모유두 세포의 배양 방법
WO2021240204A1 (fr) * 2020-05-23 2021-12-02 Pakravan Nafiseh Tête de sperme pour la résolution d'une inflammation, la régénération tissulaire, la régénération et la restauration de la fonction tissulaire : nouvelle approche de thérapie cellulaire
CN114231481B (zh) * 2021-12-21 2023-07-18 中国人民解放军总医院 一种重编程真皮成纤维细胞为内皮祖细胞的化学诱导方法
WO2023217130A1 (fr) * 2022-05-10 2023-11-16 上海赛立维生物科技有限公司 Formulation biologique contenant des cellules de type précurseur de muscle squelettique, son procédé de préparation et son application
WO2024050517A1 (fr) * 2022-09-02 2024-03-07 The University Of North Carolina At Chapel Hill Procédés de fabrication et d'utilisation de lymphocytes b reprogrammés anticancéreux
WO2025143018A1 (fr) * 2023-12-28 2025-07-03 サントリーホールディングス株式会社 Composition pour supprimer un déclin de la curiosité ou améliorer la curiosité

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US9068164B1 (en) * 1995-02-02 2015-06-30 Tristem Trading (Cyprus) Limited Method of preparing an undifferentiated cell
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US7112440B2 (en) * 1995-02-02 2006-09-26 Ghazi Jaswinder Dhoot Method of increasing the relative number of CD45 low cells in a cell population
EP0769203B1 (fr) * 1995-05-02 1999-08-18 Koninklijke Philips Electronics N.V. Tube image couleur
US20050037490A1 (en) * 1999-10-29 2005-02-17 Lawrence Rosenberg Medium for preparing dedifferentiated cells
TWI288779B (en) * 2002-03-28 2007-10-21 Blasticon Biotech Forschung Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
WO2006014642A1 (fr) * 2004-07-22 2006-02-09 Five Prime Therapeutics, Inc. Procede de production de cellules souches embryonnaires autologues
KR20110134939A (ko) * 2009-04-03 2011-12-15 더 맥클린 하스피털 코퍼레이션 유도된 다능성 줄기 세포

Also Published As

Publication number Publication date
JP6073135B2 (ja) 2017-02-01
CH704227B1 (fr) 2015-05-15
KR101766203B1 (ko) 2017-08-08
MX2012004522A (es) 2012-05-08
PH12012500714A1 (en) 2012-10-29
RU2012120713A (ru) 2013-11-27
CA2781522A1 (fr) 2011-04-28
EP2490702A1 (fr) 2012-08-29
UA109265C2 (uk) 2015-08-10
ZA201202664B (en) 2013-02-27
RU2635317C2 (ru) 2017-11-10
CN102647989A (zh) 2012-08-22
KR20120099686A (ko) 2012-09-11
AU2009354350A1 (en) 2012-04-19
CU24006B1 (es) 2014-06-27
IL218902A0 (en) 2012-06-28
AU2009354350B2 (en) 2015-09-03
TN2012000157A1 (en) 2013-12-12
JP2013508343A (ja) 2013-03-07
CU20120063A7 (es) 2012-10-15
WO2011048350A1 (fr) 2011-04-28
IL218902A (en) 2017-06-29

Similar Documents

Publication Publication Date Title
MA33740B1 (fr) Traitement à l'aide de cellules adultes matures reprogrammées
WO2006119300A3 (fr) Procede d'utilisation d'une solution aqueuse a potentiel d'oxydoreduction dans des applications dentaires
Dawidson et al. Sensory stimulation (acupuncture) increases the release of calcitonin gene-related peptide in the saliva of xerostomia sufferers
WO2006015214A3 (fr) Composition de cellules souches de cordon ombilical et methode de traitement de maladies neurologiques
WO2012071526A3 (fr) Électroporation irréversible utilisant la vascularisation tissulaire pour traiter des masses cellulaires aberrantes ou créer des échafaudages tissulaires
EA201891507A1 (ru) Кислая альфа-глюкозидаза усиленного действия для лечения болезни помпе
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
Alcocer‐Gómez et al. Effect of coenzyme Q10 on psychopathological symptoms in fibromyalgia patients
MX2009007247A (es) Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos.
NO20076382L (no) Anvendelse av dokosaheksaenglyserider i behandlingen av tumorese sykdommer
ES2571991T3 (es) Procedimientos para tratar y/o revertir enfermedades y/o trastornos neurodegenerativos
Wang et al. Low-intensity pulsed ultrasound prompts both functional and histologic improvements while upregulating the brain-derived neurotrophic factor expression after sciatic crush injury in rats
JP5030553B2 (ja) ドライマウスおよび／または唾液分泌障害を処置するための医薬
DE602005019367D1 (de) Verbesserte Zelltherapie und Gewebsregeneration mittels Stosswellen bei Patienten mit kardiovaskulären and neurologischen Krankheiten
MX2022001287A (es) Composiciones y metodos de uso de celulas madre multipotentes para reducir la enfermedad y mejorar el bienestar.
CN103006816A (zh) 一种治疗膝关节骨性关节炎的中药配方
CN117679649B (zh) 射频装置在治疗面瘫连带运动中的应用
WO2015140802A3 (fr) Système d'administration comprenant une enzyme protéolytique ou un effecteur associé destiné à utilisé dans une méthode de traitement oral et utilisations associées
WO2018039100A2 (fr) Microvésicules produites par des cellules souches pour le traitement de pathologies des tendons
WO2004043373A3 (fr) Precurseur n-acetylgalactosamine-4-sulfatase, methodes de traitement au moyen dudit enzyme et procedes de production et de purification dudit enzyme
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen
IL172499A0 (en) Method for producing retinal nerve cells from stem/progenitor cells derived from iris tissue and retinal nerve cells obtained by same method
Kadam et al. Treatment of gingival recession defect using human umbilical cord mesenchymal stem cells cultured on PCL based bone regenerating scaffold: a randomized controlled clinical study
Abdanipour et al. Effect of hydro-ethanolic extract of Chamaemelum nobile on cell prolifration and apoptosis of rat hipocample neural stem cells in the oxitative stress condition
Dai et al. p75 neurotrophin receptor positive dental pulp stem cells: new hope for patients with neurodegenerative disease and neural injury